Isolating Neural Stem Cells from Amniotic Fluid
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining human neural stem cells are limited by difficulty in isolation, slow growth kinetics, variability in donor samples, ethical concerns, and safety issues with pluripotent stem cell-derived cells, making them unsuitable for therapeutic applications.
Innovation Solution
A method for isolating human neural stem cells from amniotic fluid of a fetus diagnosed with a neural tube defect, which express specific markers like Nestin, Sox2, and ABCG2, and can be expanded long-term without losing stem cell properties, allowing for their use in therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human neural stem cells are obtained from aborted fetuses, post-mortem brains or surgical specimens, then the cells can be isolated, but the variability in donor age, storage, viability and potential contamination make it difficult to use them in therapeutic applications
Solution Approach 1:
The patent extracts neural stem cells from a specific, well-defined source (amniotic fluid) rather than using variable sources like aborted fetuses or post-mortem brains. This extraction from a controlled source eliminates donor variability while maintaining cell quality and therapeutic applicability.
2Quantity of substance
If traditional sources of human neural stem cells are used, then cells can be obtained, but limited availability, technical difficulty in harvesting, and ethical concerns arise
Solution Approach 1:
The patent utilizes amniotic fluid that is already present and accessible during prenatal procedures. The fluid naturally contains neural stem cells that can be harvested without complex surgical intervention, eliminating the need for invasive brain tissue extraction while resolving ethical concerns.
3Reliability
If the slow kinetics of human neural stem cells growth in primary cultures is accepted, then authentic neural stem cells can be maintained, but the ability to obtain enough quality cells for clinical applications is severely limited
Solution Approach 1:
The patent performs preliminary selection and isolation of neural stem cells from amniotic fluid before expansion. By pre-enriching the culture with authentic neural stem cells through specific isolation criteria (nestin expression, neurosphere formation), the subsequent expansion maintains both cell quality and achieves sufficient quantities for clinical use.
4Productivity
If immortalized neural stem/progenitor cell lines are used, then a higher capacity for proliferation is achieved, but the use of oncogenic genes and viral infection raises concerns over risk in medical-oriented applications
Solution Approach 1:
The patent uses primary neural stem cells from amniotic fluid that can be expanded to sufficient numbers for clinical application without requiring immortalization. These cells are used in a timely manner before senescence, eliminating the need for oncogenic immortalization while still achieving adequate cell quantities for therapy.
5Adaptability or versatility
If pluripotent stem cell-derived neural stem cells are used, then a new source of neural stem cells is introduced, but the possibility remains that undifferentiated cells will persist and could form teratomas
Solution Approach 1:
The patent extracts and isolates neural stem cells directly from amniotic fluid in their native, differentiated state rather than deriving them from pluripotent stem cells. This direct extraction ensures cells are already committed to the neural lineage and will not form teratomas, while maintaining the versatility of having a renewable human cell source.
Data Source
AI summary
The present invention provides a method for isolating human neural stem cells from amniotic fluid of a patient whose fetus has been diagnosed to have a neural tube defect. Use of the isolated human neural stem cells in the treatment of neurological disorders is also provided.